tiprankstipranks
Iterum Therapeutics Strategizes for NASDAQ Compliance and FDA Review
Company Announcements

Iterum Therapeutics Strategizes for NASDAQ Compliance and FDA Review

Don't Miss our Black Friday Offers:

Iterum Therapeutics (ITRM) has shared an update.

Iterum Therapeutics International Limited has contracted its outgoing Chief Medical Officer, Dr. Sailaja Puttagunta, as a consultant during the regulatory review of its new drug application for a urinary tract infection treatment. Dr. Puttagunta will be compensated at $400 per hour. Concurrently, the company is striving to regain compliance with Nasdaq Listing Rule 5550(b)(1) after being notified of a deficit in stockholders’ equity, with a deadline of September 30, 2024, to avoid delisting. Additionally, the FDA has acknowledged the resubmission of the company’s new drug application and set a review deadline for October 25, 2024.

For detailed information about ITRM stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyIterum Therapeutics regains full Nasdaq compliance
TipRanks Auto-Generated NewsdeskIterum Therapeutics’ Strategic Advances with ORLYNVAH Approval
TheFlyIterum Therapeutics reports Q3 non-GAAP EPS (24c) vs. ($1.20) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App